Acquisition Momentum Infinity Bio acquired Serimmune in June 2025, unlocking strategic integration opportunities and potential co-selling with Infinity Bio's portfolio. Position the immune intelligence platform to pharma, diagnostics, and vaccine developers seeking faster R&D outcomes.

Validated Credibility Serimmune's LymeX Phase 1 win demonstrates government and foundation validation for immune diagnostics capabilities. Leverage this credibility to engage public sector programs and disease-specific diagnostic opportunities.

Cloud Scale The platform runs on AWS and S3 with Linux infrastructure, indicating strong scalability and secure data handling. With a small team, there is value in offering turnkey data analytics, API access, and managed services to pharma and biotech customers needing scalable solutions.

Partnership Edge Past collaborations with Twist Bioscience on antibody discovery show a track record of industry partnerships. Use these references to propose co-development or supplier collaborations for therapeutic and diagnostic programs.

Growing Demand There is increasing market interest in immune intelligence to decode disease environments and accelerate diagnostics, vaccines, and therapeutics. Target large pharma, CROs, and government-funded programs with packaged offerings and integration into existing pipelines.